Cancer Family
Malignant Bone Marrow Neoplasm
CI-CAN-00000226Explore in graph →
1,035 active trials28 approved drugs633 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000226Explore in graph →
Clinical trials
4,612 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (801)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02890758 | Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 | completed | Phase 1 | 14 | Brenda Cooper, MDOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT00796068 | Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant | completed | Phase 2 | 130 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 17, 2023 | clinicaltrials |
| NCT02960646 | Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 1 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT03194932 | Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage | completed | Phase 1 | 62 | St. Jude Children's Research HospitalOTHER | 1 | Feb 14, 2023 | clinicaltrials |
| NCT04605211 | A Distress Reduction Intervention for Patients With BCR-ABL-Negative MPNs or CML on Tyrosine Kinase Inhibitors | completed | N/A | 47 | University of California, San FranciscoOTHER | 1 | Feb 13, 2023 | clinicaltrials |
| NCT03895112 | MPN-RC 118 AVID200 in Myelofibrosis | completed | Phase 1 | 21 | John MascarenhasOTHER | 1 | Feb 10, 2023 | clinicaltrials |
| NCT02743351 | Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies | completed | Phase 1 / Phase 2 | 96 | Fate TherapeuticsINDUSTRY | 1 | Feb 8, 2023 | clinicaltrials |
| NCT04518345 | TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia | completed | Early Phase 1 | 3 | Uma BorateOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT02810990 | Bosutinib in Elderly Chronic Myeloid Leukemia(BEST) | completed | Phase 2 | 65 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Feb 3, 2023 | clinicaltrials |
| NCT02088541 | Selinexor (KPT-330) in Older Patients With Relapsed AML(SOPRA) | completed | Phase 2 | 317 | Karyopharm Therapeutics IncINDUSTRY | 11 | Jan 26, 2023 | clinicaltrials |
| NCT05048615 | Low-dose Venetoclax and Azacitidine as Front-line Therapy in Newly Diagnosed AML | completed | Phase 2 | 15 | Hospital Universitario Dr. Jose E. GonzalezOTHER | 1 | Jan 25, 2023 | clinicaltrials |
| NCT05696457 | Effects of Music Therapy in Controlling Symptoms in Patients With AML and Undergoing HSCT | completed | N/A | 71 | Instituto de Investigación Sanitaria de la Fundación Jiménez DíazOTHER | 1 | Jan 25, 2023 | clinicaltrials |
| NCT02593123 | Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis | completed | Phase 2 | 31 | Virginia Commonwealth UniversityOTHER | 1 | Jan 23, 2023 | clinicaltrials |
| NCT03746041 | A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes | completed | Phase 1 | 20 | University of RochesterOTHER | 1 | Jan 23, 2023 | clinicaltrials |
| NCT03885830 | Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients | completed | — | 45 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jan 11, 2023 | clinicaltrials |
| NCT04153305 | European Registry for Myeloproliferative Neoplasms (MPNs) - Update of ERNEST Study(ERNEST) | completed | — | 1,010 | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETSOTHER | 3 | Jan 11, 2023 | clinicaltrials |
| NCT04926194 | Decidual Stromal Cells to Treat Graft-vs-Host Disease After Stem Cell Transplant for Myelodysplastic Syndrome/Myeloproliferative Neoplasm(DSC-SR) | completed | Phase 2 | 1 | University Health Network, TorontoOTHER | 1 | Jan 10, 2023 | clinicaltrials |
| NCT00075816 | Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201) | completed | Phase 3 | 551 | Medical College of WisconsinOTHER | 2 | Jan 4, 2023 | clinicaltrials |
| NCT00406393 | Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) | completed | Phase 3 | 304 | Medical College of WisconsinOTHER | 2 | Jan 4, 2023 | clinicaltrials |
| NCT04629430 | Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT(HCTDiet) | completed | N/A | 40 | University of VirginiaOTHER | 1 | Jan 4, 2023 | clinicaltrials |
| NCT02996474 | Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 10 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Dec 28, 2022 | clinicaltrials |
| NCT00423514 | Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease | completed | Phase 1 / Phase 2 | 38 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 27, 2022 | clinicaltrials |
| NCT00559091 | A Study of Ribavirin to Treat M4 and M5 Acute Myelocytic Leukemia(Borden-001) | completed | Phase 2 | 18 | Jewish General HospitalOTHER | 1 | Dec 22, 2022 | clinicaltrials |
| NCT03393611 | CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome | completed | Phase 1 | 14 | Weill Medical College of Cornell UniversityOTHER | 1 | Dec 21, 2022 | clinicaltrials |
| NCT00739141 | Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies. | completed | Phase 2 | 86 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 8, 2022 | clinicaltrials |
| NCT01272817 | Nonmyeloablative Allogeneic Transplant(Mini-allo) | completed | N/A | 36 | Scripps HealthOTHER | 1 | Nov 23, 2022 | clinicaltrials |
| NCT01364363 | Unrelated Donor Stem Cell Transplantation | completed | N/A | 64 | Scripps HealthOTHER | 1 | Nov 23, 2022 | clinicaltrials |
| NCT05619978 | French Study to Highlight the Unmet Treatment Needs of 3L+ CP-CML and With T315I-mutated CML Patients | completed | — | 200 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 17, 2022 | clinicaltrials |
| NCT03234985 | Study of Intracellular Nucleotide Pools Determination as Biomarker of the Efficacy of the Induction Treatment in Acute Myeloid Leukemia(NUCLARA) | completed | — | 83 | Hospices Civils de LyonOTHER | 1 | Nov 15, 2022 | clinicaltrials |
| NCT04543305 | A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies | completed | Phase 1 | 16 | Prelude TherapeuticsINDUSTRY | 1 | Nov 15, 2022 | clinicaltrials |
| NCT02126553 | Lenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in Remission | completed | Phase 2 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 14, 2022 | clinicaltrials |
| NCT04038437 | A Trial of CPX-351 Lower Intensity Therapy (LIT) Plus Venetoclax as First Line Treatment for Subjects With AML | completed | Phase 1 | 35 | Jazz PharmaceuticalsINDUSTRY | 1 | Nov 9, 2022 | clinicaltrials |
| NCT01685619 | AML-MDS Novel Prognostic Tests Clinical Study | completed | — | 11 | Nova Scotia Health AuthorityOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT05476562 | Study Conducted Among Patients With CML | completed | — | 3,234 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 8, 2022 | clinicaltrials |
| NCT05488613 | Healthcare Resource Utilization in Adults Diagnosed With Acute Myeloid Leukemia (AML) | completed | — | 81 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 8, 2022 | clinicaltrials |
| NCT01850004 | Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response(DASFREE) | completed | Phase 2 | 84 | Bristol-Myers SquibbINDUSTRY | 6 | Nov 3, 2022 | clinicaltrials |
| NCT02556931 | Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies | completed | Phase 2 | 117 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 3, 2022 | clinicaltrials |
| NCT04022785 | PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | completed | Phase 1 | 43 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2022 | clinicaltrials |
| NCT04424147 | Efficacy and Safety of HVA Regimens as Salvage Treatment in rrAML | completed | Phase 2 | 96 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Oct 26, 2022 | clinicaltrials |
| NCT00866918 | Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia | completed | Phase 3 | 106 | Children's Oncology GroupNETWORK | 3 | Oct 25, 2022 | clinicaltrials |
| NCT01475110 | Observational Study in Adults With Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated With Nilotinib(CML0609) | completed | — | 19 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT01586455 | Human Placental-Derived Stem Cell Transplantation(HPDSC) | completed | Phase 1 | 43 | New York Medical CollegeOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT01842672 | Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia(MITCL) | completed | Phase 1 / Phase 2 | 41 | New York Medical CollegeOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT01736683 | Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML) | completed | Phase 2 | 74 | Merck Sharp & Dohme LLCINDUSTRY | 2 | Oct 24, 2022 | clinicaltrials |
| NCT02581917 | Metabolic Changes in Blood Samples From Patients With Acute Myeloid Leukemia | completed | — | 14 | Wake Forest University Health SciencesOTHER | 1 | Oct 20, 2022 | clinicaltrials |
| NCT01700673 | Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS | completed | Phase 2 | 25 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT04416438 | COVID-19 Epidemic and Patients With Myeloproliferative Neoplasias(COVIM) | completed | — | 1,793 | French Innovative Leukemia OrganisationOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT01472107 | Study on Number and Outcome of Pregnancy in Acute Promielocitic Leukaemia (APL) Patients Treated With Chemotherapy(APL0511) | completed | — | 69 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Oct 12, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Feb 21, 2023source: clinicaltrials